文献速递白血病

DESTINY研究:酪氨酸激酶抑制剂减量后再停药治疗慢性髓性白血病

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2019-06-12

TKI先减量至半量12个月,再停药24个月。MR4组无复发生存率72%(95%CI 64-80),MMR组36%(25-53);所有复发者恢复治疗后5个月内重获MMR。

要点

  • TKI减量再停药策略在MR4患者中无复发生存率72%,在MMR患者中为36%。
  • 所有复发患者恢复治疗后5个月内均重获MMR,无疾病进展。
  • 减量后再停药可能改善无治疗缓解成功率,但机制尚不明确。

核心结论

  • 初始减量后再停药可能提高无治疗缓解方案的成功率,但其获益机制尚不明确。
  • 研究结果提示,稳定的MMR患者也值得进一步研究无治疗缓解。

研究设计与样本

  • 非随机、2期试验,在英国20家医院开展,纳入年龄≥18岁、慢性髓性白血病首次慢性期、接受TKI治疗≥3年、入组前12个月内至少3次BCR-ABL定量PCR转录本测量值<0·1%(MMR)的患者。
  • 所有PCR测量值均<0·01%的患者分配至MR4组,结果在0·1%与0·01%之间的患者分配至MMR组。
  • TKI减量至标准剂量的一半持续12个月,然后停药24个月,期间频繁进行PCR监测。
  • 主要终点为能够首先减量治疗12个月、然后完全停药2年且未丧失MMR的患者比例,采用意向性治疗分析。

主要发现

  • MR4组84例(67%)患者达到36个月试验完成点,无复发生存率为72%(95%CI 64-80)。
  • MMR组16例(33%)入组者完成研究,无复发生存率为36%(25-53)。
  • 未观察到疾病进展,发生两例无关原因死亡。
  • 所有复发患者恢复治疗后5个月内均重获MMR。

关键数值与推荐

  • 复发定义为连续两次样本PCR测量值>0·1%中的第一次,需以全剂量恢复治疗。
  • MR4定义为所有PCR测量值<0·01%;MMR组为结果在0·1%与0·01%之间。
  • TKI减量剂量为标准剂量的一半,持续12个月,然后停药24个月。

临床怎么用

  • 对于慢性髓性白血病首次慢性期、接受TKI治疗≥3年且稳定MMR或MR4的患者,可考虑先减量至半量12个月再停药24个月,并频繁监测PCR。
  • 复发(连续两次PCR>0·1%)时需以全剂量恢复治疗。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: All studies of treatment-free remission (TFR) in patients with chronic myeloid leukaemia have discontinued tyrosine kinase inhibitor (TKI) treatment abruptly and have focussed on patients with stable MR4 (BCR-ABL to ABL ratio ≤0·01%). We aimed to examine the effects of gradual treatment withdrawal and whether TFR is feasible for patients with less deep but stable remission. METHODS: The De-Escalation and Stopping Treatment with Imatinib, Nilotinib, or sprYcel (DESTINY) study is a non-randomised, phase 2 trial undertaken at 20 UK hospitals. We recruited patients (aged ≥18 years) with chronic myeloid leukaemia in first chronic phase, who had received TKI therapy for 3 years or more, with three or more BCR-ABL quantitative PCR transcript measurements (BCR-ABL to ABL1 ratio) less than 0·1% (major molecular response [MMR]) in the 12 months before entry. Patients with all PCR measurements less than 0·01% were assigned to the MR4 group. Patients with results between 0·1% and 0·01% were allocated to the MMR group. TKI treatment was de-escalated to half the standard dose for 12 months, then stopped for a further 24 months, with frequent PCR monitoring. Recurrence was defined as the first of two consecutive samples with PCR measurement greater than 0·1%, which required treatment recommencement at full dose. The primary endpoint was the proportion of patients who could first de-escalate their treatment for 12 months, and then stop treatment completely for a further 2 years, without losing MMR. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01804985. FINDINGS: Treatment at entry was imatinib (n=148), nilotinib (n=16), or dasatinib (n=10), for a median of 6·9 years (IQR 4·8-10·2). Between Dec 16, 2013, and May 6, 2015, we enrolled 49 patients into the MMR group and 125 into the MR4 group. In the MR4 group, 84 (67%) patients reached the 36-month trial completion point and recurrence-free survival was 72% (95% CI 64-80). In the MMR group, 16 (33%) entrants completed the study and recurrence-free survival was 36% (25-53). No disease progression was seen and two deaths occurred due to unrelated causes. All recurrences regained MMR within 5 months of treatment resumption. INTERPRETATION: Initial de-escalation before discontinuation might improve the success of TFR protocols, although the mechanism of its benefit is not yet clear. The findings also suggest that TFR merits further study in patients with stable MMR. FUNDING: Newcastle University and Bloodwise.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019. PMID: 31201085. doi:10.1016/S2352-3026(19)30094-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。